Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Coya Therapeutics, Inc. ( (COYA) ) has provided an update.
Coya Therapeutics reported its first-quarter financial results for 2025, highlighting significant advancements in its clinical programs. The company announced positive interim results from a study on Frontotemporal Dementia and progress in its Treg-derived exosome program. Coya also detailed improvements in inflammatory markers in Alzheimer’s patients and expanded its pipeline with COYA 303 and COYA 301. Financially, Coya reported a net loss of $7.3 million for the quarter, with increased R&D expenses driven by preclinical advancements.
The most recent analyst rating on (COYA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc., based in Houston, TX, is a clinical-stage biotechnology company focused on developing treatments that leverage the biology of regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy aimed at treating neurodegenerative, metabolic, and autoimmune diseases.
Average Trading Volume: 95,315
Technical Sentiment Signal: Sell
See more data about COYA stock on TipRanks’ Stock Analysis page.